18F-Alovudine

氟[18F]阿洛夫定

Report date: 2025/12/11 14:24:08

Base Information

Drug Name18F-Alovudine

Drug Alias Namealovudinum阿洛夫丁alovudina阿洛夫定alovudine +[7]

ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Nucleoside analoguesRadiation-emitting products > Radioactive diagnostic agentDiagnostic agent (In vivo) > Radionuclide Imaging agent +[4]

Mechanisms of ActionHuman immunodeficiency virus type 1 reverse transcriptase inhibitorsPositron-emission tomography enhancers

TargetsHuman immunodeficiency virus type 1 reverse transcriptase

Therapy Area/IndicationsDiagnostic agentsLung Neoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryMainland China

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaPhase 1 Clinical

Originator CompaniesJiangsu Huayi Nuclear Medicine Co Ltd

China Registration ClassN/A

Develop Information

Active CompaniesJiangsu Huayi Nuclear Medicine Co Ltd

Inactive CompaniesN/A

Active IndicationsDiagnostic agentsLung Neoplasms

Inactive IndicationsN/A

Other Information

ATC CodeN/A